Therefore, the development of a cardiomyocyte proliferation screening system and the finding that activation of PPARδ has the potential to improve cardiac function after MI, which could possibly be reinforced with GSK3β inhibitors, is potentially of great therapeutic value. The gene discussed is PPARD; the disease is myocardial infarction.